By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Biotechnology. According to news originating from Buffalo, New York, by NewsRx correspondents, research stated, "It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination."
Our news journalists obtained a quote from the research from Roswell Park Cancer Institute, "We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells."
According to the news editors, the research concluded: "Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses."
For more information on this research see: Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. Clinical Cancer Research, 2014;20(9):2457-2465. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - clincancerres.aacrjournals.org/)
The news correspondents report that additional information may be obtained from T. Chodon, Roswell Pk Canc Inst, Center Immunol, Buffalo, NY 14263, United States. Additional authors for this research include B. Comin-Anduix, B. Chmielowski, R.C. Koya, Z.Q. Wu, M. Auerbach, C. Ng, E. Avramis, E. Seja, A. Villanueva, T.A. McCannel, A. Ishiyama, J. Czernin, C.G. Radu, X.Y. Wang, D.W. Gjertson, A.J. Cochran, K. Cornetta and D.J.L. Wong (see also Biotechnology).
Keywords for this news article include: Antigen-Presenting Cells, Biotechnology, Buffalo, New York, Genetics, Melanomas, Immunology, Blood Cells, Lymphocytes, Vaccination, Cell Therapy, Immunization, United States, Dendritic Cells, Biological Therapy, Mononuclear Leukocytes, Hemic and Immune Systems, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC